NEW YORK (360Dx) – Opko Health today announced the filing of a premarket approval application with the US Food and Drug Administration for a total prostate-specific antigen test with the firm's Claros 1 immunoassay analyzer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.